• No results found

University of Groningen Osteoprotegerin in organ fibrosis: biomarker, actor, and target of therapy? Putri, Kurnia Sari Setio

N/A
N/A
Info
Downloaden
Protected

Academic year: 2021

Share "University of Groningen Osteoprotegerin in organ fibrosis: biomarker, actor, and target of therapy? Putri, Kurnia Sari Setio"

Copied!
3
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Download het nu ( 3 pagina )

Hele tekst

(1)

University of Groningen

Osteoprotegerin in organ fibrosis: biomarker, actor, and target of therapy?

Putri, Kurnia Sari Setio

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Putri, K. S. S. (2019). Osteoprotegerin in organ fibrosis: biomarker, actor, and target of therapy?. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Author affiliations

183

AUTHOR AFFILIATIONS

Adhyatmika Catharina Reker-Smit Marina H. de Jager Fransien van Dijk Leonie Beljaars Keri A Mangnus

Department of Pharmacokinetics, Toxicology and Targeting (PTT), Groningen Research Institute for Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands

Barbro N. Melgert Carian E. Boorsma Christina Draijer

Department of Pharmacokinetics, Toxicology and Targeting (PTT), Groningen Research Institute for Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands

GRIAC Research Institute, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Bernt van den Blink Peter Heukels

Erasmus MC, Department of Pulmonary Medicine, Rotterdam, The Netherlands. Corry-Anke Brandsma

Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

GRIAC Research Institute, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

David M. Brass

Department of Medicine, Pulmonary Division, Duke University Medical Center, Durham, NC, USA. Dorenda Oosterhuis Emilia Gore Emilia Bigaeva Peter Olinga S. Suriguga Theerut Luangmonkong Wouter L.J. Hinrichs

Department of Pharmaceutical Technology and Biopharmacy (PTB), Groningen Research Institute for Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands

(3)

Author affiliations

184

Detlef Schuppan

Institute of Translational Immunology and Research Center for Immunotherapy, University of Mainz Medical Center, Mainz, Germany.

Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, US.

George Nossent

Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Habibie

Department of Pharmacokinetics, Toxicology and Targeting (PTT), Groningen Research Institute for Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands

Faculty of Pharmacy, Universitas Hasanuddin, Makasar, Indonesia Hendrik S. Hofker

Department of Surgery, University Medical Center Groningen, The Netherlands Koert P. de Jong

Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University Medical Center Groningen, The Netherlands

Igle J. de Jong

Department of Urology, University Medical Center Groningen, The Netherlands Kurnia S.S Putri

Department of Pharmaceutical Technology and Biopharmacy (PTB), Groningen Research Institute for Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands

Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia Robbert H Cool

Department of Pharmaceutical Gene Modulation and Department of Pharmaceutical Biology, Groningen Research Institute for Pharmacy, University of Groningen, The Netherlands. Wim Timens

Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Referenties

Download het nu ( PDF - 3 pagina - 224.25 KB )

GERELATEERDE DOCUMENTEN

University of Groningen Osteoprotegerin in organ fibrosis: biomarker, actor, and target of therapy? Putri, Kurnia Sari Setio

However, recent studies have shown that higher OPG levels were not only detected in bone but also in fibrotic lung 82 , heart 83 , and vasculature 84 of murine models as well

University of Groningen Osteoprotegerin in organ fibrosis: biomarker, actor, and target of therapy? Putri, Kurnia Sari Setio

In addition, mice deficient in TNFα exhibited delayed resolution of bleomycin-induced pulmonary fibrosis, further showing that TNFα may be important in the resolution phase

University of Groningen Osteoprotegerin in organ fibrosis: biomarker, actor, and target of therapy? Putri, Kurnia Sari Setio

Cell cultures of human primary fibroblasts isolated from lung tissue of patients with pulmonary fibrosis (n=6) or patients undergoing surgical resection for carcinoma

University of Groningen Osteoprotegerin in organ fibrosis: biomarker, actor, and target of therapy? Putri, Kurnia Sari Setio

Lower levels of OPG protein excretion from pirfenidone-treated murine lung slices were not accompanied by lower levels of Col1α1 or Fn1 mRNA expression (Figures 6c, 6e),

University of Groningen Osteoprotegerin in organ fibrosis: biomarker, actor, and target of therapy? Putri, Kurnia Sari Setio

We subsequently induced the onset of fibrosis in these murine organ slices by adding profibrotic stimulus of TGFβ1 during incubation, which resulted in higher expression

University of Groningen Osteoprotegerin in organ fibrosis: biomarker, actor, and target of therapy? Putri, Kurnia Sari Setio

To confirm that IL13 can have a similar effect in liver tissue, we treated murine precision-cut liver slices with IL13 using TGFβ again as a positive control and found that IL-13

University of Groningen Osteoprotegerin in organ fibrosis: biomarker, actor, and target of therapy? Putri, Kurnia Sari Setio

In addition, we demonstrated that OPG mRNA expression was higher after transforming growth factor β1 (TGFβ1) stimulation and significantly correlated with other fibrosis

University of Groningen Osteoprotegerin in organ fibrosis: biomarker, actor, and target of therapy? Putri, Kurnia Sari Setio

Sebagai kesimpulan, tesis ini membahas tentang kadar OPG yang berhubungan erat dengan kondisi fibrosis suatu organ dan OPG dapat dideteksi dalam plasma mencit yang mengalami